NASDAQ:PTCT
Ptc Therapeutics, Inc.
Ptc Therapeutics, Inc.'s revenue grew 114.5% in fiscal 2025 to $1.7B while operating margin rose to 50.1%, its highest in 10 years. Free cash flow was $702.3M, 40.6% of revenue, and the diluted share count rose 14.9%.Summary generated from Ptc Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.7B
Revenue growth+114.5%
Revenue, 5-yr CAGR+35.4%
Gross marginn/a
Operating margin50.1%
Net margin39.4%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow$702.3M
FCF margin40.6%
Share count change+14.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 539 | 699 | 938 | 807 | 1,731 |
| Operating income | −374 | −447 | −440 | −303 | 867 |
| Net income | −524 | −559 | −627 | −363 | 683 |
| Free cash flow | −280 | −389 | −187 | −114 | 702 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 4Insider transaction report
Oct 7, 2026 - 8-KRegulation FD disclosure
Sep 21, 2026 - 8-KEntry into a material agreement
Aug 28, 2026 - 8-KRegulation FD disclosure
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KEntry into a material agreement
Jun 18, 2026